RT Journal Article
T1 Decrease in CD14++CD16+Monocytes in Low-Immunological-Risk Kidney Transplant Patients with Subclinical Borderline Inflammation
A1 Caballero, Abelardo
A1 Vazquez-Sanchez, Teresa
A1 Ruiz-Esteban, Pedro
A1 Leon, Myriam
A1 Alonso-Titos, Juana
A1 Lopez, Veronica
A1 Sola, Eugenia
A1 Gutierrez, Elena
A1 Cabello, Mercedes
A1 Casas-Gonzalez, Cristina
A1 Pozo-Alvarez, Rafael
A1 Delgado-Burgos, Juan
A1 Hernandez, Domingo
K1 kidney transplant
K1 monocytes
K1 CD14++CD16+
K1 kidney biopsy
K1 borderline lesions
K1 Rejection
K1 Monocytes
K1 Cells
K1 Prospects
K1 Biopsies
AB DefinitionWe determined the association between CD14++CD16+ monocytes and subclinical infiltrates that do not reach the histological threshold for rejection (& GE;Banff IA). We studied low-immunological-risk kidney-transplant recipients in a clinical trial (NCT02284464; EudraCT 2012-003298-24) whose protocol biopsy in the third month showed no significant changes or borderline lesions (BL). Flow cytometry was used to analyze the percentage of CD14++CD16+ monocytes in peripheral blood (PB) and blood from a fine-needle-aspiration biopsy (FNAB). A protocol biopsy was performed in 81 low-immunological-risk patients, of whom 15 were excluded (BK polyomavirus and rejection). The 28 (42.4%) with borderline lesions had significantly low levels of CD14++CD16+ in PB compared to patients with normal biopsies (7.9 & PLUSMN; 5.4 vs. 13.0 & PLUSMN; 12.8; p = 0.047). Patients without significant changes had similar percentages of CD14++CD16+ monocytes in the graft blood (GB) and FNAB blood. The percentage of these monocytes in the patients with an interstitial infiltrate, however, increased significantly in the FNAB blood compared to the GB: 16.9 & PLUSMN; 16.6 vs. 7.9 & PLUSMN; 5.4; p = 0.006. A difference of 50% in CD14++CD16+ in the GB versus the PB was a significant risk factor (p = 0.002) for BL, increasing the risk seven times. A decrease in CD14++CD16+ in the PB could be associated with the recruitment of these cells to the graft tissue in cases of subclinical BL inflammatory infiltrates below the threshold for rejection.
PB Mdpi
YR 2021
FD 2021-11-01
LK https://hdl.handle.net/10668/24496
UL https://hdl.handle.net/10668/24496
LA en
DS RISalud
RD Apr 6, 2025